ELL binding regulates U19/Eaf2 intracellular localization, stability, and transactivation

Prostate

Volumn 66, Issue 1, 2006, Pages 1-12

  Xiao, Wuhan ^a   Jiang, Feng ^a,b   Wang, Zhou ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Androgen; ELL; Prostate cancer; U19 Eaf2

Indexed keywords

ANDROGEN; BETA ACTIN; COMPLEMENTARY DNA; CYCLOHEXIMIDE; GREEN FLUORESCENT PROTEIN; LUCIFERASE; MESSENGER RNA; RED FLUORESCENT PROTEIN; RNA POLYMERASE II; TRANSCRIPTION ELONGATION FACTOR; TRANSCRIPTION ELONGATION FACTOR ELL; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR U19 EAF2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CANCER GROWTH; CELL NUCLEUS; CELL STRAIN COS7; CELL STRAIN LNCAP; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GEL MOBILITY SHIFT ASSAY; GENE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DNA BINDING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION; U19 EAF2 GENE; WESTERN BLOTTING;

BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; GENES, REPORTER; HUMANS; LUCIFERASES; MALE; MOLECULAR SEQUENCE DATA; OLIGODEOXYRIBONUCLEOTIDES; PLASMIDS; PROSTATIC NEOPLASMS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS;

EID: 29344449076     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20309     Document Type: Article

References (30)

1. Huggins C. Endocrine-induced regression of cancers. Cancer Res 1967;27:1925-1930.
2. Dai WS, Kuller LH, LaPorte RE, Gutai JP, Falvo-Gerard L, Caggiula A. The epidemiology of plasma testosterone levels in middle-aged men. Am J Epidemiol 1981;114:804-816.
3. Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 2003;91:455-461.
4. Huang H, Tindall DJ. The role of the androgen receptor in prostate cancer. Crit Rev Eukaryot Gene Expr 2002;12:193-207.
5. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 2004;61:332-353.
6. Santos AF, Huang H, Tindall DJ. The androgen receptor: A potential target for therapy of prostate cancer. Steroids 2004;69:79-85.
7. Xiao W, Zhang Q, Jiang F, Pins M, Kozlowski JM, Wang Z. Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer. Cancer Res 2003;63:4698-4704.
8. Ross RK, Pike MC, Coetzee GA, Reichardt JK, Yu Mc, Feigelson H, Stanczyk FZ, Kolonel LN, Henderson BE. Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility. Cancer Res 1998;58:4497-4504.
9. Morley JE, Kaiser FE, Perry HM III, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Carry PJ. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997;46:410-413.
10. Wang Z, Tufts R, Haleem R, Cai X. Genes regulated by androgen in the rat ventral prostate. Proc Natl Acad Sci USA 1997;94:12999-13004.
11. Pewitt EB, Haleem R, Wang Z. Adrenomedullin gene is abundantly expressed and directly regulated by androgen in the rat ventral prostate. Endocrinology 1999;140:2382-2386.
12. Cyriac J, Haleem R, Cai X, Wang Z. Androgen regulation of spermidine synthase expression in the rat prostate. Prostate 2002;50:252-261.
13. Tufts R, Cyriac J, Wang Z. Androgen regulation of the largest subunit of RNA polymerase II in the rat ventral prostate. J Steroid Biochem Mol Biol 2000;75:43-50.
14. Jiang F, Yang L, Cai X, Cyriac J, Shechter I, Wang Z. Farnesyl diphosphate synthase is abundantly expressed and regulated by androgen in rat prostatic epithelial cells. J Steroid Biochem Mol Biol 2001;78:123-130.
15. Jiang F, Wang Z. Identification of androgen-responsive genes in the rat ventral prostate by complementary deoxyribonucleic acid subtraction and microarray. Endocrinology 2003;144:1257-1265.
16. Oram S, Jiang F, Cai X, Haleem R, Dincer Z, Wang Z. Identification and characterization of an androgen-responsive gene encoding an aci-reductone dioxygenase-like protein in the rat prostate. Endocrinology 2004;145:1933-1942.
17. Simone F, Luo RT, Polak PE, Kaberlein JJ, Thirman MJ. ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties. Blood 2003;101:2355-2362.
18. Simone F, Polak PE, Kaberlein JJ, Luo RT, Levitan DA, Thirman MJ. EAF1, a novel ELL-associated factor that is delocalized by expression of the MLL-ELL fusion protein. Blood 2001;98:201-209.
19. Shilatifard A, Lane WS, Jackson KW, Conaway RC, Conaway JW. An RNA polymerase II elongation factor encoded by the human ELL gene. Science 1996;271:1873-1876.
20. Shilatifard A, Haque D, Conaway RC, Conaway JW. Structure and function of RNA polymerase II elongation factor ELL. Identification of two overlapping ELL functional domains that govern its interaction with polymerase and the ternary elongation complex. J Biol Chem 1997;272:22355-22363.
21. Thirman MJ, Levitan DA, Kobayashi H, Simon MC, Rowley JD. Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia. Proc Natl Acad Sci USA 1994;91:12110-12114.
22. Ziemin-van der Poel S, McCabe NR, Gill HJ, Espinosa R III, Patel Y, Harden A, Rubinelli P, Smith SD, LeBeau MM, Rowley JD, Diaz MO. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci USA 1991;88:10735-10739.
23. Eissenberg JC, Ma J, Gerber MA, Christensen A, Kennison JA, Shilatifard A. dELL is an essential RNA polymerase II elongation factor with a general role in development. Proc Natl Acad Sci USA 2002;99:9894-9899.
24. Elmendorf BJ, Shilatifard A, Yan Q, Conaway JW, Conaway RC. Transcription factors TFIIF, ELL, and Elongin negatively regulate SH-induced nascent transcript cleavage by non-arrested RNA polymerase II elongation intermediates. J Biol Chem 2001;76:23109-23114.
25. Gerber M, Ma J, Dean K, Eissenberg JC, Shilatifard A. Drosophila ELL is associated with actively elongating RNA polymerase II on transcriptionally active sites in vivo. EMBO J 2001;20:6104-6114.
26. Luo RT, Lavau C, Du C, Simone F, Polak PE, Kawamata S, Thirman MJ. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis. Mol Cell Biol 2001;21:5678-5687.
27. Polak PE, Simone F, Kaberlein JJ, Luo RT, Thirman MJ. ELL and EAF1 are cajal body components that are disrupted in MLL-ELL leukemia. Mol Biol Cell 2003;14:1517-1528.
28. Shinobu N, Maeda T, Aso T, Ito T, Kondo T, Koike K, Hatakeyama M. Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53. J Biol Chem 1999;274:17003-17010.
29. Wiederschain D, Kawai H, Gu J, Shilatifard A, Yuan ZM. Molecular basis of p53 functional inactivation by the leukemic protein MLL-ELL. Mol Cell Biol 2003;23:4230-4246.
30. Martinez-Garcia JF, Huq E, Quail PH. Direct targeting of light signals to a promoter element-bound transcription factor. Science 2000;288:859-863.